Nektar beats Q3 earnings estimates with a narrower-than-expected loss, but lower 2026 revenue guidance sends shares down 4.5%.
Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common stock and 2,775 restricted stock units (RSUs) to sixteen newly-hired employees under Nektar's 2025 Inducement Plan, as amended.
I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Nektar Therapeutics (NKTR).
Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here. In Q3 2026, Cedar Grove Capital Management’s Multi-Strategy Composite returned -12.7%, trailing the Russell 2000 (-7.2%), Russell Microcap (-7.4%), and S&P 500 (+2.4%). Since its January 14, 2026, inception, the composite has returned -26.2%, compared […]
2026-10-03. The following slide deck was published by Nektar Therapeutics in conjunction with this event.
Nektar Therapeutics downgraded to Hold: REZPEG shows strong efficacy but safety risks. Learn what this means for AA/AD trials and NKTR investors.
Nektar stock took a hit Thursday despite test results that suggested its drug has long-term benefits for alopecia patients.
Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria in two oral presentation sessions.
Detailed price information for Docgo Inc. (DCGO-Q) from The Globe and Mail including charting and trades.
Nektar Therapeutics (NKTR) said Wednesday that rezpegaldesleukin-associated molecular changes were d
Nektar Therapeutics recently announced that data from its Phase 2b rezpegaldesleukin trials in atopic dermatitis and alopecia areata were presented in three oral sessions at the 2026 EADV Congress in Vienna, including new 6‑month off‑treatment results in severe alopecia areata and maintenance data in atopic dermatitis. The inclusion of late‑breaking multi‑omic findings from the REZOLVE‑AD biomarker sub‑study adds an unusual level of mechanistic insight that could influence how investors...
Nektar Therapeutics (NasdaqCM:NKTR) plans three oral presentations on rezpegaldesleukin at the European Academy of Dermatology & Venereology Congress 2026. The talks will share 6‑month off‑treatment durability data from the Phase 2b REZOLVE-AA trial in severe alopecia areata. Multi‑omic biomarker findings from atopic dermatitis patients on rezpegaldesleukin are also scheduled for presentation at EADV 2026. The new rezpegaldesleukin durability and biomarker readouts come in addition to a...
Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.
All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema
(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK
A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Million Judgment Against Eli Lilly The lawsuit, filed in August 2023, stemmed from a previous licensing agreement between the two companies for the development and commercialization of the drug rezpegaldesleukin. Jury Finds Breach of Covenant The trial in the U.S
This is the newest page. Registered accounts read further back.